Abstract
Structure/receptor-based drug design, a new approach of drug discovery, has become a fascinating area of drug discovery/development. This rational approach of drug discovery may lead to the production of many drugs, and some products developed based on this approach are presently available in the market. Examples of some of these drugs include saquinavir for the treatment of AIDS, captopril against hypertension, dorzolamide for glaucoma and Zanamivir against influenza. Many molecules are designed based on their structure or receptors and are under different stages of clinical trials. For applying rational approach, we have to first identify the pathway of pathogenesis and the target proteins related to the specific disease. After the identification of the specific protein, the compound which inhibits the target protein may be designed to fit into the binding site of the protein most appropriately. Compounds from natural sources are tested first, taking cues from various kinds of information. Such compounds may form a basic structure which could be appropriated to the binding site of the target protein. This chapter has been devoted to the inhibitors of the enzymes in the arachidonic acid pathway which may serve as anti-inflammatory compounds. Target enzymes of inflammatory pathway include isozymes of phospholipase A2 (PLA2), cyclooxygenase (COX) and lipoxygenase (LOX).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aparna V, Dileep KV, Mandal PK, Karthe P, Sadasivan C, Haridas M (2012) Anti-inflammatory property of n-hexadecanoic acid: structural evidence and kinetic assessment. Chem Biol Drug Des 80:434–439. doi:10.1111/j.1747-0285.2012.01418
Ashley NT, Weil ZM, Nelson RJ (2012) Inflammation: mechanisms, costs, and natural variation. Annu Rev Ecol Evol Syst 43:385–406. doi:10.1146/annurev-ecolsys-040212-092530
Batt DG (1992) 5-lipoxygenase inhibitors and their anti-inflammatory activities. Prog Med Chem 29:1–63
Brash AR (1999) Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274:23679–23682. doi:10.1074/jbc.274.34.23679
Burke JE, Dennis EA (2009) Phospholipase A2 structure/function, mechanism, and signalling. J Lipid Res 50:S237–S242. doi:10.1194/jlr.R800033-JLR200
Cao H, Yu R, Choi Y, Ma ZZ, Zhang H, **ang W, Lee DY, Berman BM, Moudgil KD, Fong HH, van Breemen RB (2010) Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation. Pharmacol Res 61:519–524. doi:10.1016/j.phrs.2010.02
Chandra DN, Prasanth GK, Singh N, Kumar S, Jithesh O, Sadasivan C, Sharma S, Singh TP, Haridas M (2011) Identification of a novel and potent inhibitor of phospholipase A2 in a medicinal plant: crystal structure at 1.93 Å and surface Plasmon resonance analysis of phospholipase A2 complexed with berberine. Biochim et Biophys Acta (BBA) – Proteins and Proteomics 1814:657–663. doi:10.1016/j.bbapap.2011.03.002
Chandra DN, Preethidan DS, Sabu A, Haridas M, (2015) Traditional fermentation of ayurvedic medicine yields higher proinflammatory enzyme inhibition compared to wine-model product. Front in Life Sci 8(2): 160–164. doi: http://dx.doi.org/10.1080/21553769.2015.1005245
Chauret N, Yergey JA, Brideau C, Friesen RW, Mancini J, Riendeau D, Silva J, Styhler A, Trimble LA, Nicoll-Griffith DA, (2001) In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 11: 1059–1062. doi: http://dx.doi.org/10.1016/S0960-894X(01)00135-4
Chi YS, Jong HG, Son KH, Chang HW, Kang SS, Kim HP (2001) Effects of naturally occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: cyclooxygenases and lipoxygenases. Biochem Pharmacol 62:1185–1191
Cholbi R, Ferrándiz ML, Terencio MC, De Rosa S, Alcaraz MJ, Payá M (1996) Inhibition of phospholipase A2 activities and some inflammatory responses by the marine product ircinin. Naunyn Schmiedeberg’s Arch Pharmacol 354(5):677–683
Davidson FF, Hajdu J, Dennis EA (1986) 1-stearyl,2-stearoylaminodeoxy phosphatidylcholine, a potent reversible inhibitor of phospholipase A2. Biochem Biophys Res Commun 137:587–592
De Haas GH, van Oort MG, Dijkman R, Verger R (1989) Phospholipase A2 inhibitors: monoacyl, monoacylamino-glycero-phosphocholines. Biochem Soc Trans 17:274–276
Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G (2011) Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 111:6130–6185
DeWitt DL (1999) Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55:625–631
Dhanjal JK, Sreenidhi AK, Bafna K, Katiyar SP, Goyal S, Grover A, Sundar D (2015) Computational structure-based de novo design of hypothetical inhibitors against the anti-inflammatory target COX-2. PLoS One 10:e0134691. doi:10.1371/journal.pone.0134691
Dileep KV, Tintu I, Sadasivan C (2011) Molecular docking studies of curcumin analogs with phospholipase A2. Interdiscip Sci: Comput Life Sci 3:189–197. doi:10.1007/s12539-011-0090-9
Dileep KV, Remya C, Tintu I, Haridas M, Sadasivan C (2013) Interactions of selected indole derivatives with phospholipase A2: in silico and in vitro analysis. J Mol Model 19:1811–1817. doi:10.1007/s00894-012-1741-4
Dillard RD, Bach NJ, Draheim SE, Berry DR, Carlson DG, Chirgadze NY, Clawson DK, Hartley LW, Johnson LM, Jones ND, McKinney ER, Mihelich ED, Olkowski JL, Schevitz RW, Smith AC, Snyder DW, Sommers CD, Wery JP (1996) Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides. J Med Chem 39:5119–5136. doi:10.1021/jm960485v
Escrig V, Ubeda A, Ferrandiz ML, Darias J, Sanchez JM, Alcaraz MJ, Paya M (1997) Variabilin: a dual inhibitor of human secretory and cytosolic phospholipase A2 with anti-inflammatory activity. J Pharmacol Exp Ther 282:123–131
Farooqui AA, Horrocks LA, Farooqui T, (2000) Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids 106: 1–29. doi: http://dx.doi.org/10.1016/S0009-3084(00)00128-6
Flower RJ (2003) The development of COX2 inhibitors. Nat Rev Drug Discov 2:179–191. doi:10.1038/nrd1034
Furst R, Zundorf I (2014) Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediat Inflamm Article ID 146832, 9 pages. doi:10.1155/2014/146832
Garcia-Pastor P, Randazzo A, Gomez-Paloma L, Alcaraz MJ, Paya M (1999) Effects of petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation. J Pharmacol Exp Ther 289:166–172
Gelb MH, Jain MK, Berg OG (1994) Inhibition of phospholipase A2. FASEB J 8(12):916–924
Habeeb AG, Rao PPN, Knaus EE (2000) Design and syntheses of diarylisoxazoles: novel inhibitors of cyclooxygenase-2 (COX-2) with analgesic-antiinflammatory activity. Drug Dev Res 51(4):273–286. doi:10.1002/ddr.9
Habeeb AG, Rao PPN, Knaus EE (2001) Design and synthesis of 4,5-Diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity. J Med Chem 44(18):2921–2927. doi:10.1021/jm0101287
Hansford KA, Reid RC, Clark CI, Tyndall JDA, Whitehouse MW, Guthrie T, McGeary RP, Schafer K, Martin JL, Fairlie DP (2003) D-tyrosine as a chiral precursor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (Imia) with antiinflammatory activity. Chembiochem 4:181–185. doi:10.1002/cbic.200390029
Hofmann B, Steinhilber D (2013) 5-lipoxygenase inhibitors: a review of recent patents (2010–2012). Expert Opin Ther Pat B:895–909. doi:10.1517/13543776.2013.791678
Kang JH, Zheng T, Mr M, Js S, Lee J, Ke D, Hong S, Cui M, Choi S, Hw C, Hy PC, Yim M (2015) 5-lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression. Bioorg Med Chem 23:7069–7078. doi:10.1016/j.bmc. 2015.09.025
Kim HH, Kim DH, Kim MH, Oh MH, Kim SR, Park KJ, Lee MW (2013) Flavonoid constituents in the leaves of Myrica rubra Sieb. Et Zucc. With anti-inflammatory activity. Arch Pharm Res 36:1533–1540. doi:10.1007/s12272-013-0147-x
Leone S, Ottani A, Bertolini A (2007) Dual acting anti-inflammatory drugs. Curr Top Med Chem 7:265–275
Li CS, Brideau C, Chan CC, Savoie C, Claveau D, Charleson S, Gordon R, Greig G, Gauthier JY, Lau CK, Riendeau D, Thérien M, Wong E, Prasit P (2003) Pyridazinones as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 13:597–600. doi:10.1016/S0960-894X(02)01045-4
Mayer AM (1989) Manoalide: a new phospholipase A2 inhibitor of marine origin with potential immunoregulatory effect. Med (B Aires) 49:175–180
Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428–435. doi:10.1038/nature07201
Meirer K, Steinhilber D, Proschak E (2014) Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. Basic Clin Pharmacol Toxicol 114:83–91. doi:10.1111/bcpt.12134
Montuschi P, Sala A, Dahlén SE, Folco G (2007) Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today 12:404–412. doi:10.1016/j.drudis.2007.03.004
Naveen CD, Prasanth GK, Sadasivan C, Haridas M (2013) Evaluation of bio-transformed berberine derivatives as anti-inflammatory drugs: an in silico study. Interdiscip Sci: Comput Life Sci 4:268–272. doi:10.1007/s12539-012-0142-9
Oinuma H, Takamura T, Hasegawa T, Nomoto K, Naitoh T, Daiku Y, Hamano S, Kakisawa H, Minami N (1991) Synthesis and biological evaluation of substituted benzenesulfonamides as novel potent membrane-bound phospholipase A2 inhibitors. J Med Chem 34:2260–2267
Rao P, Knaus EE (2008) Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 11:81s–110s
Rao PPN, Amini M, Li H, Habeeb AG, Knaus EE (2003) Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. J Med Chem 46:4872–4882. doi:10.1021/jm0302391
Rao PNP, Uddin MJ, Knaus EE (2004) Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. J Med Chem 47:3972–3990. doi:10.1021/jm049939b
Rimon G, Sidhu RS, Lauver DA, Lee JY, Sharma NP, Yuan C, Frieler RA, Trievel RC, Lucchesi BR, Smith WL (2011) Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci 107:28–33
Rossi A, Pergola C, Koeberle A, Hoffmann M, Dehm F, Bramanti P, Cuzzocrea S, Werz O, Sautebin L (2010) The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. Br J Pharmacol 161:555–570. doi:10.1111/j.1476-5381.2010.00930.x
Rouzer CA, Marnett LJ (2009) Cyclooxygenases: structural and functional insights. J Lipid Res 50:S29–S34. doi:10.1194/jlr.R800042-JLR200
Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387–437
Snyder DW, Bach NJ, Dillard RD, Draheim SE, Carlson DG, Fox N, Roehm NW, Armstrong CT, Chang CH, Hartley LW, Johnson LM, Roman CR, Smith AC, Song M, Fleisch JH (1999) Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: a new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther 288:1117–1124
Springer DM, Luh BY, Bronson JJ, McElhone KE, Mansuri MM, Gregor KR, Nettleton DO, Stanley PL, Tramposch KM (2000) Biaryldiacid inhibitors of human s-PLA2 with anti-inflammatory activity. Bioorg Med Chem 8:1087–1109
Steinhilber D, Hofmann B (2014) Recent advances in the search for novel 5-lipoxygenase inhibitors. Basic Clin Pharmacol Toxicol 114:70–77
Talley JJ (1999) Selective inhibitors of cyclooxygenase-2 (COX-2). Prog Med Chem Res 36:201–234
Tomy MJ, Dileep KV, Prasanth S, Preethidan DS, Sabu A, Sadasivan C, Haridas M (2014a) Cuminaldehyde as a lipoxygenase inhibitor: in vitro and in silico validation. Appl Biochem Biotechnol 174:388–397
Tomy MJ, Sharanya CS, Dileep KV, Prasanth S, Sabu A, Sadasivan C, Haridas M (2014b) Derivatives form better lipoxygenase inhibitors than piperine: In vitro and in silico study. Chem Biol Drug Des 85:715–721
Tramposch KM, Steiner SA, Stanley PL, Nettleton DO, Franson RC, Lewin AH, Carroll FI (1992) Novel inhibitor of phospholipase A2 with topical anti-inflammatory activity. Biochem Biophys Res Commun 189:272–279
Tramposch KM, Chilton FH, Stanley PL, Franson RC, Havens MB, Nettleton DO, Davern LB, Darling IM, Bonney RJ (1994) Inhibitor of phospholipase A2 blocks eicosanoid and platelet activating factor biosynthesis and has topical anti-inflammatory activity. J Pharmacol Exp Ther 271:852–859
Van Breemen RB, Tao Y, Li W (2011) Cyclooxygenase-2 inhibitors in ginger (Zingiber officinale). Fitoterapia 82:38–43. doi:10.1016/j.fitote.2010.09.004
Werz O (2004) 5-lipoxygenase: regulation and pharmacology. Med Chem Rev 1(2):201–223. doi:10.2174/1567203043480331
Werz O, Steinhilber D (2005) Development of 5-lipoxygenase inhibitors--lessons from cellular enzyme regulation. Biochem Pharmacol 70:327–333. doi:10.1016/j.bcp.2005.04.018
Werz O, Steinhilber D (2006) Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 112:701–718. doi:10.1016/j.pharmthera.2006.05.009
Zhang X, Hung TM, Phuong PT, Ngoc TM, Min BS, Song KS, Seong YH, Bae K (2006) Anti-inflammatory activity of flavonoids from Populus davidiana. Arch Pharm Res 29:1102–1108
Zimmermann KC, Sarbia M, Schrör K, Weber AA, (1998) Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 54: 536–540. doi: https://doi.org/10.1124/mol.54.3.536
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Sharanya, C.S., Haridas, M. (2017). Anti-inflammatory Molecules: Enzyme Inhibitors. In: Sugathan, S., Pradeep, N., Abdulhameed, S. (eds) Bioresources and Bioprocess in Biotechnology. Springer, Singapore. https://doi.org/10.1007/978-981-10-4284-3_9
Download citation
DOI: https://doi.org/10.1007/978-981-10-4284-3_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-4282-9
Online ISBN: 978-981-10-4284-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)